ArticleFrontiers in public health2023
Risk of newly diagnosed interstitial lung disease after COVID-19 and impact of vaccination: a nationwide population-based cohort study.
Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- A Two-Level, Multidimensional Framework for Understanding and Treating Clinician Fatigue.Health care analysis : HCA : journal of health philosophy and policy · 2026Article
- Phytochemicals as potential inhibitors of NETosis: implications for immunothrombosis and chronic disease management.BMC complementary medicine and therapies · 2026Article
- Association between gastroesophageal reflux disease and incident bronchiectasis: a nationwide representative population-based study in Korea.BMC pulmonary medicine · 2025Article
- Immunophenotyping of bronchoalveolar lavage and functional impairment in post-COVID syndrome : Insights from a prospective cohort trial.Wiener klinische Wochenschrift · 2025Observational
- Risk of Stroke in COVID-19 Survivors With Asthma: A Nationwide, Population-Based Cohort Study.Journal of Korean medical science · 2025Article
- Risk of pneumonia in individuals with rheumatoid arthritis: a nationwide cohort study.BMJ open respiratory research · 2025Article
- Effects of Vaccination on Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Nationwide Population-Based Cohort Study.Tuberculosis and respiratory diseases · 2025Article
- Clinical impacts of COVID-19 on severe exacerbation and mortality in interstitial lung disease: prognosis 30 days after infection.The Korean journal of internal medicine · 2025Article
- Exacerbation and mortality risk in individuals with bronchiectasis post-COVID-19 recovery.ERJ open research · 2025Article
- Air Pollution Increases Healthcare Utilization Below Safe Thresholds in Individuals With Asthma.Allergy, asthma & immunology research · 2025Article
- Article
- Association between rheumatoid arthritis and interstitial lung disease and impact of serologic status: a large-scale longitudinal study.Scientific reports · 2025Article
- COVID-19 and Long-term Risk of Ischemic Heart Disease in Asthma.Allergy, asthma & immunology research · 2025Article
- Impact of physical activity on all-cause mortality in individuals with non-cystic fibrosis bronchiectasis.Frontiers in medicine · 2025Article
- Prognostic Implications of Initial Radiological Findings of Pulmonary Fibrosis in Patients with Acute SARS-CoV-2 Infection: A Prospective Multicentric Study.Diseases (Basel, Switzerland) · 2024Article
- Tuberculosis and osteoporotic fracture risk: development of individualized fracture risk estimation prediction model using a nationwide cohort study.Frontiers in public health · 2024Article
- Impact of exercise maintenance on mortality in interstitial lung disease: a population-based retrospective cohort study.Therapeutic advances in respiratory diseaseArticle
- Incidence and risk factors for idiopathic pulmonary fibrosis in individuals aged 75 years and older in an ultra-aging society.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Previous studies suggested that coronavirus disease 2019 (COVID-19) could lead to pulmonary fibrosis, but the incidence of newly diagnosed interstitial lung disease (ILD) after COVID-19 is unclear. We aimed to determine whether COVID-19 increases the risk of newly diagnosed ILD and whether vaccination against COVID-19 can reduce this risk. Methods: This retrospective cohort study used data from the Korean National Health Insurance claim-based database. Two study groups and propensity score (PS)-matched control groups were constructed: Study 1: participants diagnosed with COVID-19 (COVID-19 cohort) and their PS-matched controls; Study 2: COVID-19 vaccinated participants (vaccination cohort) and their PS-matched controls. Results: In Study 1, during a median 6 months of follow-up, 0.50% of the COVID-19 cohort (300/60,518) and 0.04% of controls (27/60,518) developed newly diagnosed ILD, with an incidence of 9.76 and 0.88 per 1,000 person-years, respectively. The COVID-19 cohort had a higher risk of ILD [adjusted hazard ratio (aHR), 11.01; 95% confidence interval (CI), 7.42-16.32] than controls. In Study 2, the vaccination cohort had a lower risk of newly diagnosed ILD than controls (aHR, 0.44; 95% CI, 0.34-0.57). Conclusion: Using nationwide data, we demonstrated that COVID-19 was associated with a higher incidence rate of newly diagnosed ILD, but that this risk could be mitigated by COVID-19 vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.